Adults newly diagnosed with active Crohn’s disease benefit from immediate treatment with advanced therapies, including immunomodulators and biologic anti–tumor necrosis factor agents, rather than the traditional step-up method that reserves biologics and immunomodulators for later in treatment, according to results of a new randomized controlled trial.
However, a biomarker that the investigators thought could help guide treatment choices proved to not be helpful in decision